[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subarachnoid-hemorrhage-aneurysmal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subarachnoid-hemorrhage-aneurysmal":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,49,73,107,148,177,203,246,269,295,318,343,367,393,416,444,474,503,524,553,579,605,631,653],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642376","endovascular-therapy-for-cerebral-vasospasm-after-aneurysmal-subarachnoid-hemorrhage-100642376",false,"NCT07643922","Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage","Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: The RESCUE-CV Randomized Trial","RESCUE-CV","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. Aged 18 to 80 years.\n2. SAH confirmed by cranial CT, with an intracranial aneurysm identified by CTA, MRA, or DSA and determined to be the source of bleeding.\n3. Prior treatment of the aneurysm by endovascular intervention or surgical clipping.\n4. Evidence suggestive of CVS within 14 days after onset, defined by at least one of the following:\n\n   1. Clinical deterioration, including a decrease in GCS score of \\>2 points and\u002For a new focal neurological deficit not attributable to another known neurological cause;\n   2. TCD confirmed vasospasm, defined as mean flow velocity (MFV) \\>120 cm\u002Fs in the middle cerebral artery (MCA) and Lindegaard ratio \\>3, after excluding other causes of increased flow velocity such as anemia or fever;\n   3. Vasospasm confirmed by DSA or CTA.\n\nExclusion Criteria:\n\n1. Hunt-Hess grade 5 with critical illness and inability to tolerate intervention.\n2. Contraindications to milrinone, including milrinone allergy, aortic or pulmonary valve stenosis, obstructive hypertrophic cardiomyopathy, acute coronary syndrome, or malignant arrhythmia.\n3. Perioperative procedure-related complications that may interfere with study assessment, such as significant stenosis of the parent artery.\n4. Irreversible cerebral infarction involving the entire vascular territory affected by vasospasm.\n5. Poor blood pressure control, defined as systolic blood pressure \\\u003C100 mmHg.\n6. Non-aneurysmal SAH, including hemorrhage due to arteriovenous malformation, vasculitis, tumor bleeding, trauma, or other non-spontaneous causes, or cases without an identified bleeding source.\n7. Other severe neurological disorders with substantial pre-existing disability (mRS \\>3), such as progressive cognitive impairment or status epilepticus.\n8. Severe systemic disease, including significant cardiac, hepatic, renal, or psychiatric disorders.\n9. Pregnant or breastfeeding women, or women planning pregnancy during the study period.\n10. Any other condition considered by the investigators to make the patient unsuitable for participation or likely to limit compliance with study procedures.\n11. Current participation in another interventional clinical study, inability to complete follow-up assessments, or failure to provide informed consent.","ALL","18 Years","80 Years",{"count":21,"type":22},306,"ESTIMATED","INTERVENTIONAL",[25],"NA","Cerebral vasospasm is a common and serious complication after aneurysmal subarachnoid hemorrhage and is an important cause of delayed cerebral ischemia and poor neurological outcomes. Although standardized medical management is widely used, effective treatment options for cerebral vasospasm remain limited.\n\nEndovascular treatment, including intra-arterial drug infusion and mechanical angioplasty, may relieve vasospasm and improve cerebral perfusion after aneurysmal subarachnoid hemorrhage. However, most available evidence comes from retrospective or observational studies, and high-quality randomized evidence remains insufficient. Milrinone is a phosphodiesterase inhibitor with multiple potentially beneficial effects, including vasodilation, positive inotropic activity, anti-inflammatory properties, and endothelial protection. These effects may make milrinone a promising therapeutic agent for relieving cerebral vasospasm, reducing delayed cerebral ischemia, and ultimately improving clinical outcomes after aneurysmal subarachnoid hemorrhage.\n\nThis study is a multicenter, prospective, randomized controlled clinical trial designed to evaluate whether early continuous milrinone-based endovascular therapy improves outcomes in patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Eligible participants will be randomly assigned to receive either standardized medical management alone or milrinone-based endovascular therapy plus standardized medical management. In the intervention group, patients will receive intra-arterial milrinone during endovascular treatment, with mechanical angioplasty when clinically indicated, followed by continuous intravenous milrinone infusion for 72 hours after intra-arterial administration.\n\nThe study will evaluate whether this continuous treatment strategy reduces poor neurological outcomes at 3 months after randomization. It will also assess the effects of treatment on delayed cerebral ischemia, vasospasm resolution, cognitive function, quality of life and so on. The results of this trial may provide high-quality evidence for early continuous milrinone-based endovascular therapy as a treatment strategy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage.",[28,29],"Subarachnoid Hemorrhage, Aneurysmal","Cerebral Vasospasm After Subarachnoid Hemorrhage",[31,32,33,34,35],"aneurysmal subarachnoid hemorrhage","Cerebral vasospasm","Milrinone","Endovascular Therapy","Outcomes","RECRUITING","2026-06-25",{"date":39,"type":40},"2026-06-29","ACTUAL",{"date":42,"type":40},"2026-06-03",{"date":44,"type":22},"2029-12-31",{"name":46,"class":47},"Beijing Tiantan Hospital","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100587765","continuous-assessment-of-brain-blood-perfusion-in-subarachnoid-hemorrhage-patients-using-near-infrared-spectroscopy-nirs-100587765","NCT06932640","Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)","Continuous Assessment of Cerebral Autoregulation in Subarachnoid Hemorrhage (SAH) Patients Using Cerebral Oximetry Index and Hemoglobin Volume Reactivity Index","Inclusion Criteria:\n\n* Patients aged 18 to 89 years who are admitted to the Neurological Intensive Care Unit (Neuro ICU) between March 2025 and December 2026 for aneurysmal subarachnoid hemorrhage (SAH).\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Prisoners\n* Pregnant women\n* Patients enrolled in concurrent ongoing interventional trial\n* Students of UAB\n* Employees of UAB\n* Patients who undergoes frontal decompression surgery resulting bone flap deficit where NIRS monitoring pads could not be applied.","89 Years",{"count":58,"type":22},120,"OBSERVATIONAL","The goal of this observational study is to continuously assess cerebral autoregulation in patients with subarachnoid hemorrhage (SAH) using cerebral oximetry index (COx) and hemoglobin volume reactivity index (HVx). The main question it aims to answer is: Whether optimal perfusion pressure is dynamic and changes with time in patients with SAH, and that autoregulation is disrupted in patients during the course of SAH, contributing to delayed cerebral ischemia (DCI).",[28],"NOT_YET_RECRUITING","2026-06-08",{"date":65,"type":40},"2026-06-09",{"date":67,"type":22},"2026-07-01",{"date":69,"type":22},"2028-12",{"name":71,"class":47},"University of Alabama at Birmingham",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":72},"100447217","safety-feasibility-and-efficacy-of-non-invasive-vagus-nerve-stimulation-nvns-in-the-treatment-of-aneurysmal-subarachnoid-hemorrhage-100447217","NCT05103566","Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage","STORM: Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage","STORM","Inclusion Criteria:\n\n* Male or female, 18-85 years of age\n* Ruptured aneurysmal SAH confirmed by angiography and repaired by neurosurgical clipping or endovascular occlusion (coiling)\n* Modified Glasgow Coma Scale (mGCS) score ≥ 10 and Hunt Hess 1-4 within 72 hours of presumed aneurysm rupture\n* Enrollment and initiation of nVNS treatment must occur within 72 hours of presumed aneurysm rupture\n* Provide a legally obtained informed consent form from the participant or the legally authorized representative (LAR); telephonic consent is acceptable\n* Female participants of reproductive age must have a negative pregnancy test result (urine or blood)\n\nExclusion Criteria:\n\n* Use of any concomitant electrostimulation device, including a pacemaker, defibrillator, or deep brain stimulator\n* No plan to secure aneurysm, defined as aneurysm that has not been surgically or endovascularly treated\n* Previous neck dissection or radiation\n* History of carotid artery disease or carotid surgery\u002Fdissection\n* History of secondary or tertiary heart blocks, ventricular tachycardia, or supraventricular tachycardia (SVT; including atrial fibrillation)\n* Screws, metals, or devices in the neck\n* Currently participating in an investigational drug or device clinical trial with potential to confound data collection","85 Years",{"count":83,"type":22},25,[25],"This is a single-site, single-arm, open-label pilot study assessing the safety, feasibility, and efficacy of non-invasive vagus nerve stimulation (nVNS), gammaCore, for the acute treatment of aneurysmal subarachnoid hemorrhage (SAH) subjects in a neurocritical care setting. 25 patients will be enrolled, all treated with an active device. The primary efficacy outcomes are reduced aneurysm rupture rate, reduced seizure and seizure-spectrum activity, minimized hemorrhage grades, and increased survival.",[28],[88,89,90,91,92,93,94,95,96,97],"Aneurysm","Hemorrhage","Intracranial Hemorrhages","Cerebrovascular Disorders","Intracranial Aneurysm","Vascular Diseases","Aneurysm, Brain","Brain Diseases","Central Nervous System Diseases","Aneurysm, Ruptured","2026-05-11",{"date":100,"type":40},"2026-05-14",{"date":102,"type":40},"2022-10-04",{"date":104,"type":22},"2029-04",{"name":106,"class":47},"Massachusetts General Hospital",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":72},"100637552","prospective-observational-multimodal-neuromonitoring-in-adult-nsicu-patients-100637552","NCT07577713","Prospective Observational Multimodal Neuromonitoring in Adult NSICU Patients","Prospective Observational Multimodal Neuromonitoring in Adult Neurosciences Intensive Care Unit Patients: Characterization of Noninvasive Cerebral Autoregulation Indices, Quantitative EEG, and Physiologic Correlates Across NSICU Diagnoses","Inclusion Criteria:\n\n* Age 18 years or older\n* Admitted to the NSICU at UT Southwestern Medical Center\n* Informed consent obtained from subject or legally authorized representative (as defined under Texas Health and Safety Code Section 166.039), or consent process underway per institutional policy\n* At least one study monitoring modality feasible (SedLine qEEG and\u002For Brain4Care extensometry); NIRS data collected where already in standard clinical use\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Prisoner status\n* Active declination of participation by subject or legally authorized representative\n* Absence of both subject and legally authorized representative consent when required\n* Clinical condition preventing safe placement of any study monitor (e.g., extensive facial or scalp injury, surgical dressings or hardware at all possible sensor sites, open wounds at sensor locations, severe uncontrolled agitation)\n* Anticipated clinical data capture insufficient for meaningful analysis\n* Urgent clinical priorities making research monitor placement inappropriate at time of approach\n* Inability to provide informed consent in English; study consent materials are available in English only",{"count":115,"type":22},300,"This is a prospective observational cohort study of adult patients admitted to the Neurosciences Intensive Care Unit (NSICU) at UT Southwestern Medical Center. The study acquires multimodal neuromonitoring data - including SedLine quantitative EEG (qEEG) from standard-of-care monitoring, Brain4Care (B4C) noninvasive intracranial dynamics monitoring, and near-infrared spectroscopy (NIRS)-derived cerebral autoregulation (CA) indices where NIRS is already in clinical use - and links these data to bedside physiologic, medication, diagnostic, and clinical outcome variables during standard care. No alteration of clinical management occurs. The study prioritizes aneurysmal subarachnoid hemorrhage (aSAH) patients to characterize the natural history of noninvasive CA parameter evolution through the delayed cerebral ischemia (DCI) window (admission through Day 14) and provides preliminary data for subsequent interventional study design.",[28,118,119,120,121,122],"Brain Injuries, Traumatic","Cerebral Hemorrhage","Ischemic Stroke","Delayed Emergence From Anesthesia","Encephalopathy",[31,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139],"delayed cerebral ischemia","cerebral autoregulation","CPPopt","MAPopt","Brain4Care","SedLine","quantitative EEG","near-infrared spectroscopy","COx","TOxA","transcranial Doppler","neurocritical care","NSICU","noninvasive intracranial monitoring","Moberg Clinical Platform","multimodal neuromonitoring","2026-05-04",{"date":98,"type":40},{"date":143,"type":22},"2026-07",{"date":145,"type":22},"2029-09",{"name":147,"class":47},"University of Texas Southwestern Medical Center",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":174,"leadSponsor":176,"locationsCount":72},"100638580","noninvasive-ca-monitoring-validation-and-autonomic-modulation-in-aneurysmal-subarachnoid-hemorrhage-100638580","NCT07577739","Noninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage","Non-Invasive Cerebral Autoregulation Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage: A Two-Component Prospective Study of EVD Clamping Validation, CA Natural History, and the Effects of Cervical Sympathetic Block and Transcutaneous Auricular Vagal Nerve Stimulation on Cerebral Autoregulation Parameters","Inclusion Criteria (Component 1 - All Enrolled Participants):\n\n* Age 18 years or older\n* Primary diagnosis of aneurysmal subarachnoid hemorrhage (aSAH), confirmed by imaging\n* Admitted to the NSICU at Clements University Hospital, UT Southwestern Medical Center\n* Informed consent obtained from subject or legally authorized representative (as defined under Texas Health and Safety Code Section 166.039)\n* Brain4Care extensometry sensor placeable at an appropriate cranial site not occluded by surgical dressings or EVD hardware\n* Open EVD with active continuous ICP monitoring (required for EVD clamping sub-protocol only; not required for Aims 2 or 3)\n\nExclusion Criteria (Component 1):\n\n* Age younger than 18 years\n* Prisoner status\n* Primary NSICU admission diagnosis other than aSAH\n* Active declination by subject or legally authorized representative\n* Brain4Care sensor not placeable at any accessible cranial site\n* Active clinical deterioration making research monitoring impractical at time of approach\n* Physician-of-record declining research enrollment for clinical reasons\n* Inability to provide informed consent in English\n* Known pregnancy at time of enrollment\n\nAdditional Inclusion Criteria for Component 2 (Aim 3 - CSB and taVNS):\n\n* At least one successful EVD clamping session completed\n* PI documentation of Component 2 operational readiness, co-signed by qualified co-investigator or Department Director\n* INR 1.5 or less and platelet count 50,000\u002FuL or greater within 24 hours prior to each CSB procedure\n* No active infection or cellulitis at right anterolateral neck\n* No known allergy to ropivacaine or amide local anesthetics\n* No contralateral phrenic nerve palsy or severe pre-existing respiratory compromise\n* No cardiac pacemaker or implanted cardiac device contraindicating taVNS\n* No allergy to electrode adhesive materials\n* Continuous cardiac telemetry active and interpretable\n* Resting HR 60 bpm or greater on two readings within 24 hours prior to session\n* No current use of Class I or III antiarrhythmic medications\n* No clinically significant AV conduction abnormality\n\nAdditional Exclusion Criteria for Component 2:\n\n* Prior ipsilateral right-sided cervical surgery, radiation, or known anatomical distortion precluding safe C6 approach\n* Hemodynamic instability with active vasopressor escalation at time of planned CSB\n* Active uncontrolled tachyarrhythmia or bradyarrhythmia at time of taVNS session\n* Physician-of-record declining autonomic modulation procedures for any clinical reason\n* Known or suspected pregnancy",{"count":115,"type":22},[25],"This is a two-component prospective study of adult aneurysmal subarachnoid hemorrhage (aSAH) patients admitted to the Neurosciences Intensive Care Unit (NSICU) at UT Southwestern Medical Center. Component 1 (active upon IRB approval) validates Brain4Care (B4C) extensometry-derived noninvasive cerebral autoregulation (CA) indices against invasive ICP-derived equivalents in aSAH patients with open external ventricular drains (EVDs), and characterizes the prospective natural history of multi-modal CA parameter evolution through the delayed cerebral ischemia (DCI) window (admission through Day 14). Component 2 (activated upon PI readiness declaration) assesses the within-subject effect of cervical sympathetic block (CSB) and transcutaneous auricular vagal nerve stimulation (taVNS) on CA parameters in enrolled aSAH patients.",[28,159,160,161],"Delayed Cerebral Ischemia","Cerebral Vasospasm","Autonomic Nervous System Diseases",[31,124,125,126,127,163,128,164,165,166,167,168,169,170,131,171,135],"pressure reactivity index","cervical sympathetic block","stellate ganglion block","transcutaneous auricular vagal nerve stimulation","taVNS","autonomic modulation","EVD clamping","external ventricular drain","noninvasive ICP monitoring",{"date":98,"type":40},{"date":143,"type":22},{"date":175,"type":22},"2030-06",{"name":147,"class":47},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":72},"100632053","pronostic-factors-in-elderly-patients-admitted-to-the-intensive-care-unit-for-aneurysmal-subarachnoid-hemorrhage-100632053","NCT07508683","Pronostic Factors in Elderly Patients Admitted to the Intensive Care Unit for Aneurysmal Subarachnoid Hemorrhage","Pronostic Factors in Elderly Patients Admitted to the Intensive Care Unit for Aneurysmal Subarachnoid Hemorrhage Multicenter Retrospective Observational Study FAPPAR-HSA","FAPPAR-HSA","Inclusion Criteria:\n\n* Patients hospitalized in ICU for aneurysmal subarachnoid hemorrhage\n* Aged 70 years or over the day of admission in ICU\n* Between Juin 30, 2021 and Juin 30, 2025\n\nExclusion Criteria:\n\n* Decline to participate",{"count":186,"type":22},170,"Subarachnoid hemorrhage (SAH) represents a significant proportion of hemorrhagic strokes. Severe SAH in elderly patients is associated with poorer outcomes compared to younger cohorts. Better characterization of both short- and long -term prognosis in these patients is necessary to facilitate medical decision-making in the intensive care unit (ICU)\n\nPrimary Objective:\n\nThe primary objective is to identify prognostic factors associated with poor functional outcome or death at 6 months (± 2 months) in elderly patients admitted to the ICU for SAH.\n\nSecondary Objectives:\n\nTo evaluate in-hospital mortality among elderly patients admitted to the ICU for SAH.\n\nTo describe the causes of in-hospital death (brain death, withholding\u002Fwithdrawal of life-sustaining treatment \\[WOLST\\], other medico-surgical causes) in elderly patients admitted to the ICU for SAH.\n\nTo describe the care trajectory following hospital discharge for elderly patients admitted to the ICU for SAH.\n\nTo evaluate the mean length of stay in the ICU and in the hospital (acute care) for elderly patients admitted to the ICU for SAH.\n\nTo identify prognostic factors associated with poor functional outcome or death at 1 year in elderly patients admitted to the ICU for SAH.",[28],[190,191,192,193],"Subarachnoid Hemorrhage","Elderly","Prognostic Factors","Intensive Care Unit","2026-03-31",{"date":196,"type":40},"2026-04-02",{"date":198,"type":22},"2026-05",{"date":200,"type":22},"2027-03",{"name":202,"class":47},"Central Hospital, Nancy, France",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":211,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":213,"conditions":214,"keywords":220,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":245},"100624514","augmented-renal-clearance-in-neurocritical-care-100624514","NCT07410624","Augmented Renal Clearance in Neurocritical Care","Augmented Renal Clearance in Neurocritical Care Population: A Prospective Multicenter Study","Neuro-ARC","Inclusion Criteria:\n\n1. Age 18-85 years\n2. Admitted to ICU at one of the participating sites\n3. Diagnosis: SAH, TBI, ICH, meningitis, SE or ischemic stroke\n4. Provision of informed consent\n5. Foley catheter in place at time of consent (to facilitate urine collection)\n\nExclusion Criteria:\n\n1. Incarceration\n2. Anticipated ICU length of stay is \\\u003C 72 hours (insufficient time for monitoring)",{"count":212,"type":22},512,"Stroke, severe brain injury, uncontrolled seizures and brain infections are the most common life-threatening neurological illnesses in the world with an estimated combined annual hospital management cost of up to 44 billion dollars. Seizures and infections are common complications following acute neurological illnesses and contribute significantly to poor outcomes if not promptly treated with appropriately dosed anti-seizure medications and antibiotics, respectively. Limited research suggested that many of those patients present with a phenomenon called augmented renal clearance (ARC) or, in other words, enhanced kidney function. ARC may have a significant influence on how medications are removed from the body potentially resulting in insufficient doses and treatment failure. Therefore, patients with ARC require higher medication doses; however, ARC is largely undetected using kidney assessment methods currently used in practice. In addition, it is not clear how medications should be dosed in those with ARC. The majority of ARC research has not focused on patients with life-threatening neurological illnesses. Thus, clinicians are likely under-dosing vital medications in those patients, and completely unaware. There is an immediate need to address the gap in knowledge. Therefore, this research aims to characterize the phenomenon of ARC in patients with life-threatening neurological illnesses through identifying the frequency, duration, contributing factors and clinical impact of ARC. Adult patients admitted to the neurosciences intensive care unit for life-threatening neurological illnesses will be enrolled in the study. Urine and blood samples wil be collected from participants to determine the presence of ARC and identify its contributing factors. In addition, blood samples will be collected from participants treated with select antibiotics and anti-seizure medications to determine their concentration and propose dose adjustment in those with ARC. This research is expected to improve the care of patients with life-threatening neurological illnesses through efficient identification and monitoring of patients exhibiting ARC facilitating timely medication dosage optimization. Furthermore, recommendations of optimal doses of commonly used medications in patients with ARC would improve the likelihood of treatment success with potential to improve patients' health and wellbeing.",[215,216,217,218,28,120,219],"TBI (Traumatic Brain Injury)","Status Epilepticus","Bacterial Meningitis","Augmented Renal Clearance (ARC)","Intracerebral Hemorrhage",[221,222,223,224,225,226,227,228,229,230,231,232,233,234,235],"traumatic brain injury","seizures","status epilepticus","bacterial meningitis","brain infections","neuro-ICU","augmented renal clearance (ARC)","augmented kidney function","creatinine clearance","neurological injury","TBI","ARC","subarachnoid hemorrhage","ischemic stroke","antimicrobials","2026-02-15",{"date":238,"type":40},"2026-02-18",{"date":240,"type":40},"2021-10-01",{"date":242,"type":22},"2026-09-30",{"name":244,"class":47},"University of Alberta",3,{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":254,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":268,"locationsCount":245},"100598008","nimodipine-variability-in-sah-100598008","NCT07065903","Nimodipine Variability in SAH","Nimodipine Systemic Exposure and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Multi-centre Observational Study (ASH-II Study)","ASH-II","Inclusion Criteria:\n\n* Age 18-85 years\n* Diagnosis of aneurysmal SAH\n* Provision of informed consent\n* Treated with nimodipine\n* Presence of intravascular catheter at the time of sampling\n\nExclusion Criteria:\n\n* Anticipated hospital length of stay \\\u003C48 hours\n* Non-aneurysmal SAH\n* Not treated with nimodipine\n* Incarceration\n* Delayed presentation to the hospital (\\>96 h from SAH onset)",{"count":255,"type":22},500,"Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening neurological illness: it is bleeding in the brain after a bulging blood vessel (a brain aneurysm) ruptures. Although SAH accounts for only 5% of all strokes, it often happens in middle age and it puts a significant burden on many patients during their most productive years. Complications following SAH are common, and they can cause major long-term disability. Only one medication - nimodipine - has been proven to benefit the health and wellbeing of these patients. All SAH patients should receive nimodipine for 21 days at a fixed dose. However, our early work suggested that all patients are not getting equal amounts of nimodipine into their blood. In addition, the two different forms (structural mirror images) of nimodipine might have different effects. Reduced amounts of nimodipine in the blood may lessen its benefit and contribute to worsening health and wellbeing of SAH patients.\n\nThe overall goal of this research is to see what happens with different nimodipine doses and to confirm whether the two forms of nimodipine have different effects. The investigators will conduct a multi-centre study in adult patients admitted for SAH in Canada and the USA. The investigators will collect blood samples to determine the amount of each type of nimodipine in each participant's body, and then will check to see how each participant is doing at 90 days following SAH. They will also check other factors affecting nimodipine levels, so that they can in the future suggest dose recommendations that are actually tailored to each patient.",[258,28],"Subarachnoid Aneurysm Hemorrhage",[260,233,261],"nimodipine","pharmacokinetics","2026-02-04",{"date":264,"type":40},"2026-02-09",{"date":266,"type":40},"2024-05-13",{"date":145,"type":22},{"name":244,"class":47},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":72},"100615554","phase-2-infusion-of-lidocaine-and-steroids-in-middle-meningeal-artery-for-pain-in-subarachnoid-hemorrhage-100615554","NCT07294118","Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage","Endovascular Infusion of Lidocaine and Steroids in the Middle Meningeal Artery for Pain Management in Spontaneous Subarachnoid Hemorrhage Patients","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosed with aneurysmal SAH, Hunt and Hess Grades 1-2.\n* Consent to study procedures and follow-up evaluations.\n\nExclusion Criteria:\n\n* Known allergies to lidocaine or steroids.\n* Arteriovenous malformations.\n* Dural Arteriovenous Fistulas.\n* Other significant intracranial pathologies.\n* Hemodynamic instability preventing safe intervention.\n* Previous MMA interventions.\n* Previous craniotomies or need for craniotomy.\n* Need for external ventricular drain.","100 Years",{"count":278,"type":22},15,[280],"PHASE2","The goal of this clinical trial is to learn if an infusion of lidocaine, with or without steroids, into the middle meningeal artery (MMA) helps relieve severe headaches in patients with spontaneous subarachnoid hemorrhage (SAH). It will also study the safety of this treatment.",[28,283,284,285],"Headache","Opiate Dependence","Opioid Use","2026-01-07",{"date":288,"type":40},"2026-01-09",{"date":290,"type":40},"2026-01-02",{"date":292,"type":22},"2027-08",{"name":294,"class":47},"The University of Texas Medical Branch, Galveston",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":72},"100525232","phase-4-telavancin-blood-and-cerebrospinal-fluid-concentrations-in-patients-with-external-ventricular-drainage-100525232","NCT06119061","Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage","Inclusion Criteria:\n\n* Adult aged 18-85 years\n* Actively draining ventriculostomy\n\nExclusion Criteria:\n\n* history of hypersensitivity to telavancin or similar agents\n* reduced renal function (estimated creatinine clearance \\\u003C 50\u002Fml) at the time of consent\n* severe anemia (hemoglobin \\\u003C 7gm\u002Fdl)\n* vulnerable population (pregnant, prisoner)\n* concomitant antimicrobial therapy",{"count":302,"type":22},20,[304],"PHASE4","The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old.\n\nSubjects will receive telavancin 10mg\u002Fkg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.",[28],[261,308],"augmented renal clearance","2025-12-23",{"date":311,"type":40},"2025-12-26",{"date":313,"type":40},"2024-07-02",{"date":315,"type":22},"2026-12",{"name":317,"class":47},"Aaron Cook",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":331,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100516766","phase-2-block-sah---ppf-block-for-post-sah-headache-100516766","NCT06008795","BLOCK-SAH - PPF-Block for Post-SAH Headache","Pterygopalatine Fossa (PPF) Block as an Opioid Sparing Treatment for Acute Headache in Spontaneous Subarachnoid Hemorrhage","BLOCK-SAH","In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated ICF by participant or a legally authorized representative (LAR)\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged ≥18 and ≤ 85 years\n4. Admitted with a primary diagnosis of spontaneous, non-traumatic, SAH within 72 hours of ictus hemorrhage\n5. Disease-specific inclusion criteria:\n\n   1. Spontaneous, non-traumatic SAH\n   2. Subarachnoid pattern of hemorrhage warranting diagnostic DSA due to involvement of at least one of the following regions: quadrigeminal plate, prepontine cistern, perimesencephalic cistern, Sylvian fissure, or surrounding Circle of Willis\n   3. Modified Fisher grade 1-4 (on presentation imaging)\n   4. Hunt and Hess 1-3 or World Federation of Neurosurgeons grade 1-4 (on screening, included only if also fulfilling Glasgow Coma Scale verbal subscore ≥4)\n   5. Minimum Glasgow Coma Scale verbal subscore of 4 (on screening)\n6. Able to verbalize pain scale scores according to 11-point numeric pain scale\n\n   In order to be enrolled and undergo randomization in this study, an individual must meet all of the additional criteria:\n7. Stabilization period criteria:\n\n   1. A minimum of 4 hours from DSA with clipping or coiling procedure (whenever applicable)\n   2. Successful treatment of culprit vascular lesion (i.e., ≥90% obliteration of aneurysm), when applicable\n8. Requiring a minimum of 15mg OME prn for headache analgesia during any 24-hour period during eligibility period\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Premorbid conditions:\n\n   1. Pre-existing neurologic, psychiatric, or other condition that would confound neurologic assessment or would make difficult\u002Fimpossible to accurately assess neurologic and\u002For functional outcome\n   2. Pre-existing diffuse flow-limiting narrowing of arteries in the Circle of Willis, regardless of etiology (e.g., atherosclerosis, vasculitis, Moya-Moya syndrome)\n   3. Prior use of opioid or barbiturate analgesics for at least two-thirds of the days in previous month, regardless of indication\n   4. Diagnosis of substance use disorder in the previous year\n   5. Infected or wounded skin, or a skin lesion at the site of puncture for PPF- injection\n2. Uncorrected coagulopathy\n\n   1. Platelet count \\\u003C 50,000\u002FμL, International Normalized Ratio (INR) \\> 1.7\n   2. Requiring use of systemic anticoagulation and antiplatelet therapy (except for aspirin monotherapy).\n3. SAH-specific:\n\n   1. Head trauma as etiology of SAH\n   2. Infection as cause for aneurysm or SAH (i.e., mycotic aneurysms)\n   3. Inability to successfully treat culprit vascular lesion\n   4. Diffuse vasospasm on pre-enrollment diagnostic CTA or DSA. Vasospasm is defined as moderate-to-severe arterial narrowing on DSA or CTA not attributable to atherosclerosis, catheter-induced spasm, or vessel hypoplasia, as determined by a neuroradiologist or neurointerventionalist\n4. Standard pain regimen conditions\n\n   1. Elevation of hepatic enzymes prohibiting use of scheduled APAP (i.e., AST or ALT \\> 3x upper limit level)\n   2. Chronic liver condition with absolute contra-indication for APAP (even at lower maximum daily doses)\n5. Participation in a concurrent investigational\u002Finterventional study (observational studies allowed)\n6. Known to be pregnant, or with a positive pregnancy test\n7. Allergy or intolerance to the medications used in the PPF-block (i.e., ropivacaine, dexamethasone) or standard pain regimen (APAP)\n8. Vulnerable populations such as prisoners and inmates (abiding GCP per the study IRB)\n9. Unable to receive first PPF-injection within 96 hours of ictus hemorrhage",{"count":327,"type":22},195,[280],"BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injections with 20mg ropivacaine + 4mg dexamethasone (active, PPF-block) compared to saline (placebo) for headache in survivors of aneurysmal subarachnoid hemorrhage (SAH), while monitoring intracranial arterial mean flow velocities with transcranial Doppler (TCD) peri-intervention (intervention = PPF-injections: active or placebo)",[28,283],[332],"Pterygopalatine Fossa Nerve Block","2025-11-25",{"date":335,"type":40},"2025-11-28",{"date":337,"type":40},"2023-12-17",{"date":339,"type":22},"2027-02-28",{"name":341,"class":47},"University of Florida",11,{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":23,"phases":353,"briefSummary":354,"conditions":355,"keywords":356,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":72},"100518591","remote-ischemic-conditioning-in-aneurysmal-sah-100518591","NCT06032533","Remote Ischemic Conditioning in Aneurysmal SAH","The Effect of Remote Ischemic Conditioning on Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Prospective, Randomized, Patient-assessor Blinded, Sham-controlled Pilot Study Investigating Effect on Clinical Outcome.","RESCUE-SAH","Inclusion Criteria:\n\n* Aneurysmal subarachnoid hemorrhage confirmed by computed tomography (CT) with aneurysm origin confirmed by computed tomography angiography (CTA) or digital subtraction angiography (DSA)\n* Aneurysmal subarachnoid hemorrhage symptom-onset ≤ 3 days\n* Aneurysm protected by clipping or coiling\n* Independent in daily living before symptom onset (mRS ≤ 2)\n\nExclusion Criteria:\n\n* Subarachnoid hemorrhage caused by a lesion other than cerebral aneurysm\n* Symptomatic vasospasm at the time of enrollment\n* Previous cerebral lesion e.g. symptomatic cerebral infarction (\\>2cm), multiple sclerosis, symptomatic intracerebral hemorrhage, tumour, prior neurosurgery (excluding prior clipping or coiling of cold aneurysms without complications).\n* History of severe peripheral vascular disease or signs of severe peripheral vascular disease on physical examination\n* History of deep vein thrombosis or signs of deep vein thrombosis on physical examination\n* Kidney involvement or prior kidney disease with an estimated glomerular filtration rate (eGFR) below safe levels for contrast infusion in relation to CT-perfusion.\n* Pregnancy (Women of child-bearing age will have serum-Humane Choriogonadotropine taken prior to final inclusion. If pregnancy cannot be ruled out,the patient can't be included. Women with a safe birth control method will be encouraged to use this method during the entire period of active treatment.)\n* Concomitant other acute life-threatening medical or surgical condition",{"count":352,"type":22},100,[25],"The goal of this clinical trial is to examine the effect of limb occlusion therapy (remote ischemic conditioning, RIC) in subjects with aneurysmal subarachnoid hemorrhage.\n\nThe main question it aims to answer is whether RIC can improve long-term recovery in participants with aneurysmal subarachnoid hemorrhage.\n\nResearchers will compare levels of functional independence in participants in the RIC-group to participants in the sham-group.",[28,159],[357,190,88,159],"Remote Ischemic Conditioning","2025-09-30",{"date":360,"type":40},"2025-10-03",{"date":362,"type":40},"2023-09-09",{"date":364,"type":22},"2027-11-30",{"name":366,"class":47},"Aarhus University Hospital",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":72},"100397018","hippocampal-volume-and-memory-functions-in-aneurysmal-subarachnoid-hemorrhage-100397018","NCT04449666","Hippocampal Volume and Memory Functions in Aneurysmal Subarachnoid Hemorrhage","Investigation of the Relationship Between Hippocampal Volume and Memory Functions in in Patients With Aneurysmal Subarachnoid Hemorrhage (aSAH)","Inclusion Criteria:\n\n* neurological rehabilitation patients in phase B - D\n* at minimum eight weeks after disease onset\n* aneurysmal subarachnoid hemorrhage (Hunt \\& Hess grade I or II)\n* written consent from the patient's legal representative\n* exclusion of pregnancy\n\nExclusion Criteria:\n\n* insufficient cardiorespiratory stability\n* previous brain damage\n* mental disorders (dementia, depression)\n* colonization with multi-resistant pathogens\n* MRI contraindications\n* claustrophobia\n* weight \\> 120 kg","70 Years",{"count":376,"type":22},30,"Neuropsychological and functional long-term consequences of subarachnoid hemorrhages (SAH) represent a great challenge, since sometimes considerable cognitive deficits occur without evidence of substantial brain damage. In this study, we want to examine if the frequently observed memory deficits are associated with hippocampal atrophy.",[379,28],"Neurologic Disorder",[381,382,383],"Neurological rehabilitation","Hippocampal volume","Memory deficits","2025-09-18",{"date":386,"type":40},"2025-09-19",{"date":388,"type":40},"2020-06-15",{"date":390,"type":22},"2026-12-15",{"name":392,"class":47},"BDH-Klinik Hessisch Oldendorf",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":72},"100579081","safety--feasibility-and-preliminary-efficacy-of-remote-ischemic-conditioning-in-patients-with-aneurysmal-subarachnoid-hemorrhage-after-aneurysm-clipping-100579081","NCT06819657","Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping","Remote Ischemic Conditioning for Safety, Feasibility, and Preliminary Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping: An Open-Label, Evaluator-Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n1. Imaging examination confirmed aneurysmal subarachnoid hemorrhage.\n2. Responsible aneurysms received craniotomy clipping within 24 hours.\n3. 18≤ age ≤80 years old.\n4. Informed consent of the participant or legally authorized representative\n\nExclusion Criteria:\n\n1. Patients with other types of cerebral hemorrhage.\n2. Prior neurological impairment (mRS Score \\>1) or mental illness may confuse neurological or functional assessment.\n3. Severe comorbidities with a life expectancy of less than 90 days.\n4. Refractory hypertension (systolic blood pressure 180\\>mmHg or diastolic blood pressure 110\\>mmHg).\n5. RIC contraindications: severe soft tissue injury of lower limbs.\n6. Simultaneously participate in another research program to study a different experimental therapy.\n7. Any condition that the investigator believes may increase the patient's risk.",{"count":401,"type":22},40,[25],"This study was designed to evaluate the safety and efficacy of remote ischemic conditioning (RIC) in patients with aneurysmal subarachnoid hemorrhage (aSAH) following surgical clipping.\n\nAneurysmal subarachnoid hemorrhage is a life-threatening condition that occurs when a cerebral aneurysm ruptures, causing bleeding into the subarachnoid space. Surgical clipping of the aneurysm is a standard procedure used to stop the bleeding and prevent re-rupture, thereby stabilizing the patient's condition.\n\nRemote ischemic conditioning (RIC) is a non-invasive treatment that involves using a blood pressure cuff to induce brief, temporary cycles of ischemia and reperfusion in a limb. Research suggests that this process may confer systemic protective effects, potentially improving recovery from brain injury or surgery. Although RIC has shown potential to improve outcomes in patients with other neurological conditions, its effect on patients with aSAH who undergo surgical clipping remains unclear.\n\nThis study will evaluate whether RIC can reduce complications, improve neurological function, and enhance overall recovery in these patients. The findings will help determine whether RIC should be incorporated into the standard treatment regimen for aSAH.",[28,91,95,405,406,93,407],"Stroke","Cardiovascular Diseases","Nervous System Diseases","2025-09-08",{"date":410,"type":40},"2025-09-09",{"date":412,"type":40},"2025-03-10",{"date":414,"type":22},"2026-03-30",{"name":46,"class":47},{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":424,"targetDuration":426,"studyType":59,"phases":4,"briefSummary":427,"conditions":428,"keywords":432,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":72},"100574987","ai-models-for-cerebral-aneurysms-segmentation-detection-and-stability-prediction-100574987","NCT06766422","AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction","Artificial Intelligence Applications for Cerebral Aneurysms Segmentation, Detection and Stability Prediction: a Stepwise, Multicenter Study","AI-CARE","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Preliminary diagnosis or symptoms indicating the presence or potential presence of a cerebral aneurysm;\n3. Undergoing a non-contrast head MRA or contrast-enhanced head\u002Fneck CTA;\n4. The patient or their legal representative is able and willing to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Other intracranial vascular diseases: moyamoya disease, arteriovenous malformations, arteriovenous fistulas, arterial occlusions, and arterial dissections;\n2. History of intracranial arterial interventions: stent placement, partial aneurysm coil treatment, etc.;\n3. Severe allergy to contrast agents or absolute contraindications to iodine-based contrast agents;\n4. Renal insufficiency with elevated serum creatinine (greater than twice the upper normal limit);\n5. MRI contraindications: pacemakers, claustrophobia, etc.;\n6. Diseases or conditions that affect the quality of CTA\u002FMRA images;\n7. Inability to complete the study due to psychiatric disorders, cognitive, or emotional disturbances.\n\nNote: The CTA sub-study does not include exclusion criterion 5; the MRA sub-study does not include exclusion criteria 3 and 4.",{"count":425,"type":22},10000,"1 Year","Aneurysmal subarachnoid hemorrhage (SAH) is one of the critical diseases that severely threaten human health, with a clinical mortality rate reaching as high as 30%. Early diagnosis and intervention before rupture are considered key to improving the prognosis of aneurysmal SAH. With the widespread clinical application of non-invasive cerebrovascular imaging techniques, such as CTA and MRA, the detection rate of unruptured intracranial aneurysms (UIAs) has significantly increased. However, addressing the growing demand for clinical cerebrovascular imaging diagnostics raises the challenge of improving diagnostic accuracy while alleviating the workload of diagnostic physicians. Furthermore, considering that not all detected UIAs will rupture, it is crucial to accurately identify high-risk aneurysms prone to rupture to avoid unnecessary overtreatment, which could lead to significant socioeconomic burdens and iatrogenic harm to patients.To meet this clinical need, researchers have developed an artificial intelligence (AI) algorithm to create software capable of automatically identifying intracranial aneurysms based on non-invasive vascular imaging data, enabling accurate diagnosis of aneurysms. To evaluate the clinical utility of this AI algorithm, a prospective, multicenter, registry study was proposed. Through long-term standardized and uniform non-invasive imaging follow-up, individualized imaging analysis profiles will be established. By correlating these profiles with aneurysm outcome events (growth or rupture), imaging features capable of accurately predicting aneurysm growth and rupture will be identified and analyzed. This approach is expected to enhance the accuracy of UIA diagnosis and enable risk stratification for unruptured intracranial aneurysms through the utilization of relevant data.",[429,430,28,431],"Unruptured Cerebral Aneurysm","Artificial Intelligence (AI)","Magnetic Resonance Angiography",[433,434,431,190],"Artificial Intelligence","Cerebral Aneurysms","2025-05-31",{"date":437,"type":40},"2025-06-03",{"date":439,"type":40},"2025-01-10",{"date":441,"type":22},"2027-06-30",{"name":443,"class":47},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":23,"phases":454,"briefSummary":455,"conditions":456,"keywords":462,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":470,"locationsCount":473},"100415967","phase-2-effect-of-xenon-on-brain-injury-after-aneurysmal-subarachnoid-hemorrhage-100415967","NCT04696523","Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage","Effect of Xenon on Brain Injury, Neurological Outcome and Survival in Patients After Aneurysmal Subarachnoid Hemorrhage","Xe-SAH","Inclusion Criteria:\n\nTo be considered eligible to participate in this study, a SAH subject must meet the inclusion criteria listed below:\n\n1. Informed consent obtained from the next of kin or legal representative\n2. Aneurysmal subarachnoid hemorrhage visible on CTA or DSA.\n3. Deterioration of consciousness to Hunt-Hess 3-5\n4. Age of ≥ 18 years\n5. Intubated.\n6. GCS 3-12 obtained off neuromuscular blocking agents\n7. Xenon treatment can be started within 6 hours after onset of SAH symptoms\n\nExclusion Criteria:\n\nAn aSAH subject may not be enrolled in the trial if he\u002Fshe meets any one of the exclusion criteria below:\n\n1. Acute or chronic traumatic brain injury\n2. Maximum diameter of intracerebral hemorrhage \\> 2.5 cm\n3. Pneumothorax or pneumomediastinum,\n4. Acute lung injury requiring ≥ 60% FIO2 (fraction of inspired oxygen).\n5. Systolic arterial pressure \\\u003C 80 mmHg or mean arterial pressure \\\u003C 60 mmHg for over 30 min period\n6. Bilaterally fixed and dilated pupils\n7. Positive pregnancy test, known pregnancy, or current breast-feeding\n8. Neurological deficiency due to traumatic brain injury or other neurological illness\n9. Imminent death or current life-threatening disease\n10. Current enrollment in another interventional study\n11. The subject is known to have clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the subject to participate in this clinical trial.\n12. Presence of implants or foreign bodies which are not known to be MRI safe",{"count":453,"type":22},160,[280],"An investigator-initiated clinical drug study\n\nMain Objective:\n\nTo explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH).\n\nPrimary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI).\n\nAfter confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups:\n\nControl group: Standard of Care (SOC) group: Air\u002Foxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air\u002Foxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug\u002Ftreatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen\u002Fair.\n\nComparative drug(s)\u002Fplacebo\u002Ftreatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports.\n\nDuration of treatment: 24 hours\n\nAssessments:\n\nBaseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered.\n\nAcute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https:\u002F\u002Fwww.commondataelements.ninds.nih.gov\u002FSAH.aspx#tab=Data\\_Standards.",[28,457,458,459,460,461],"Cerebral Injury","Cerebral Ischemia","Cerebral Infarction","Cardiac Event","Cardiac Failure",[463],"xenon, neuroprotection, aneurysmal subarachnoid hemorrhage","2025-04-28",{"date":466,"type":40},"2025-05-01",{"date":468,"type":40},"2025-04-22",{"date":44,"type":22},{"name":471,"class":472},"Turku University Hospital","OTHER_GOV",7,{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":481,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":482,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":72},"100585750","mechanisms-of-brain-heart-injury-of-post-intracranial-hemorrhage-100585750","NCT06906432","Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage","Multimodal Omics and Imaging Study on the Mechanisms of Brain-heart Injury in Patients With Intracranial Hemorrhage","Inclusion Criteria:\n\n1. Patients aged 18 years or older at the time of enrollment.\n2. Acute intracranial hemorrhage confirmed by neuroimaging (CT, MRI，CTA, MRA, or DSA) within 48 hours of symptom onset.\n3. Ability to provide informed consent or have a legally authorized representative willing to consent on their behalf.\n\nExclusion Criteria:\n\n1. Patients who refuse to participate in the study or cannot provide informed consent.\n2. Patients with a history of significant cardiovascular disease, including myocardial infarction, heart failure, or arrhythmias, unless stable and well-controlled.\n3. Patients who have undergone cardiac bypass surgery, stent placement, or other cardiovascular interventions within the past 6 months.\n4. Patients with active brain tumors, ischemic stroke within 3 months or a history of previous brain injury that could confound the study findings.\n5. Patients with active malignant disease, severe inflammatory or infectious disease, or those who have undergone surgery for any reason within the past 3 months.\n6. Patients with any condition that, in the opinion of the investigator, would make it unsafe or impractical to participate in the study.",true,{"count":483,"type":22},1000,"Intracranial hemorrhage is a condition characterized by high mortality rates and suboptimal functional outcomes. It precipitates both direct brain injury and subsequent secondary injuries, including delayed cerebral ischemia, brain edema, and hydrocephalus. Complications such as cardiac injury may also arise, categorizing them within the cerebrocardiac syndrome (CCS). The clinical spectrum of CCS encompasses acute myocardial injury, acute coronary syndrome, left ventricular systolic and diastolic dysfunction, cardiac arrhythmias, and sudden cardiac death, all of which are associated with increased mortality and deterioration in patient status. The precise pathophysiological mechanisms underlying both cerebral and cardiac injuries remain enigmatic, and the implications for diagnosis and therapeutic strategies are yet to be fully explored.\n\nIn this study, we propose to enroll patients with intracranial hemorrhage who will undergo conventional treatment and comprehensive multidisciplinary evaluations. Our observational research is grounded in a multimodal omics and imaging approach, aimed at investigating both local and systemic injuries subsequent to intracranial hemorrhage. This comprehensive strategy is intended to facilitate precise diagnosis, risk stratification, and clinical decision-making, while also shedding light on the pathophysiological mechanisms involved.\n\nThe primary objectives of this research are to address the following key questions:\n\n* \\[Question 1\\] What are the pathophysiological mechanisms underlying cardiac injury in patients with intracranial hemorrhage?\n* \\[Question 2\\] What are the pathophysiological mechanisms responsible for early and delayed brain injuries following intracranial hemorrhage?\\"",[28,486,487,488,489,490,491,492,159,493,494,219],"Cerebrocardiac Syndrome","Mass Spectrometry","Heart Failure","Atrial Fibrillation","Ischemic Heart Disease","Heart Infarction","Arrhythmias, Cardiac","Hydrocephalus","Vasospasm, Cerebral","2025-03-29",{"date":497,"type":40},"2025-04-02",{"date":499,"type":40},"2024-08-01",{"date":501,"type":22},"2036-12-01",{"name":46,"class":47},{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":513,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":72},"100543739","phase-2-complement-inhibition-attacking-the-overshooting-inflammation-fter-subarachnoid-hemorrhage-ciaosah-100543739","NCT06359782","Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)","A Phase II Trial on the Safety and Efficacy of C1 Inhibitor for the Acute Management of Subarachnoid Hemorrhage","CIAO@SAH","Inclusion Criteria:\n\n* Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan;\n* Age ≥ 18 years on admission;\n* WFNS grade 1-5.\n\nExclusion Criteria:\n\n* Subarachnoid hemorrhage deemed most likely of 'peri mesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (not originated from an aneurysm and patients have by definition a favourable clinical outcome)\n* Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (does not occur spontaneous)\n* Participation in another clinical therapeutic study;\n* Patients with definite infaust prognosis on arrival and\u002For expected death within 24 hours of admission\n* Patients with a known hereditary complement deficiency (including hereditary angioedema);\n* Patients with a history of sensibility to blood products or C1-inhibitor;\n* Patients with a history of thrombosis (when known at time of inclusion);\n* Pregnant woman",{"count":512,"type":22},128,[280],"Aneurysmal subarachnoid hemorrhage (SAH) can lead to devastating outcomes for patients, like cognitive decline. This is caused by early brain injury (EBI) followed by delayed cerebral ischemia (DCI). Neuroinflammation, triggered by the complement system, has been investigated to be a key mediator in the pathophysiology of EBI and DCI. Inhibition of the complement system is therefore considered to be a potentially important new treatment for SAH.\n\nThis trial aims to study the safety and efficacy of C1-inhibitor Cinryze, an approved inhibitor of the complement system, compared to placebo in patients with SAH. By temporarily blocking the complement system we hypothesize limitation of delayed cerebral ischemia and a more favourable clinical outcome for SAH patients due to a decrease in the inflammatory response.",[28],"2024-12-23",{"date":518,"type":40},"2024-12-27",{"date":520,"type":40},"2024-11-04",{"date":200,"type":22},{"name":523,"class":47},"Haaglanden Medical Centre",{"id":525,"slug":526,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":532,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":534,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":72},"100400125","prevention-of-vasospasm-in-sah-through-csf-treatment-100400125","NCT04490161","Prevention of Vasospasm in SAH Through CSF Treatment","Prevention of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Through Treatment With Intravenous Autologous Cerebrospinal Fluid - a Pilot Trial.","PREVAIL","Inclusion Criteria:\n\nAge: \\>18, \\\u003C90\n\n* SAH HH 3 - 5\n* Cerebral saccular Aneurysm\n* Digital subtraction angiography prior to aneurysm repair\n* Aneurysm repair within 72h\n* Modified Fisher Grade 3+4\n* Presence of aneurysm needing treatment (clipping or coiling)\n* Treatment within 24 hours of symptom onset\n* External ventricular drain (clinical need)\n\nExclusion Criteria:\n\n* Non-aneurysmal SAH\n\n  * SAH HH\\\u003C3\n  * Extensive intraventricular haemorrhage (unable to obtain CSF without massive aspiration of clotted blood)\n  * Contraindication for digital subtraction angiography\n  * Aneurysm repair \\>72h after rupture\n  * Signs of radiographic vasospasm upon diagnosis\n  * Presence of systemic or CSF infection\n  * Contraindication for oral Nimodipin\n  * Pregnancy","90 Years",{"count":302,"type":22},[25],"The pathophysiological mechanisms of aneurysmal subarachnoid haemorrhage (aSAH) involve early brain injury (EBI) and delayed cerebral ischemia (DCI).\n\nSeveral mechanisms contribute to EBI pathogenesis, including cell death, inflammatory response, oxidative stress, excitotoxicity, microcirculatory dysfunction, microthrombosis and cortical spreading depolarization. All are suggested to be linked due to common pathogenic pathways and direct interaction.\n\nDespite advances in research of diagnostics and treatment strategies, brain injury remains the major cause of death and disability in SAH patients. There is no sufficient treatment of SAH and its devastating consequences known so far. Developing and improving diagnostic methods to monitor SAH patients and to evaluate efficacy of treatment strategies are essential in SAH research. These include neuroimaging, biomarkers, and other parameters such as invasive multimodal neuromonitoring and intraoperative electrophysiological monitoring.\n\nCerebral vasospasm (CV) - mostly responsible for DCI - can be depicted on angiograms. Altogether, tremendous efforts have been taken to conquer the occurrence and sustainability of CV. The mortality of patients suffering aSAH rises up to 50% if the patients' condition is critical (Hunt\\&Hess (HH) Grade 5, WFNS Grade 5, modified Fisher Grade 4).\n\nReports of beneficial outcome in patients with pre-existing CSF shunting have been published. The hypothesis of early CSF reapplication to the bloodstream, in order to prevent CV seems to be positively approved by the mentioned reports. Nevertheless, no data could be found on the mechanisms of action in this phenomenon.\n\nTo confirm the presence of interaction of the mechanisms of EBI and evaluate the application of cerebrospinal fluid (CSF), a pilot clinical trial was planned. Due to the lack of validated animal models for aSAH it is necessary to perform the trial first-in-human. A pilot (proof of concept) trial - is done through inclusion of 10 patients with severe aSAH (≥HH4). According to clinical guidelines, these patients receive external ventricular drainages in order to drain CSF and lower intracranial pressure. An interim analysis of data will be performed after inclusion and treatment of 5 patients. Blood-\u002FCSF-sampling for further analysis will be collected before, during and after treatment according to the study protocol.",[190,28,494,537],"Aneurysmal Subarachnoid Hemorrhage",[539,88,540,541,542,543],"EVD","SAH","Subarachnoid hemorrhage","cerebral vasospasm","cerebrospinal fluid","2024-11-25",{"date":546,"type":40},"2024-11-27",{"date":548,"type":40},"2020-01-01",{"date":550,"type":22},"2025-02-01",{"name":552,"class":47},"Medical University Innsbruck",{"id":554,"slug":555,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":23,"phases":563,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":575,"leadSponsor":577,"locationsCount":72},"100559049","phase-3-ultra-early-statin-in-patients-with-aneurysmal-subarachnoid-hemorrhage-ue-star-100559049","NCT06559072","Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)","Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR): a Randomized Controlled Trial","Ue-STAR","Inclusion Criteria:\n\n1. Male or female; Aged ≥18 years\n2. Signs and symptoms presumed aneurysmal subarachnoid hemorrhage, confirmed by radiological evidence\n3. Treatment within 6 h after symptom onset\n\nExclusion Criteria:\n\n1. Treatment with statin prior SAH\n2. Non-aSAH (e.g. traumatic subarachnoid hemorrhage, arteriovenous malformation)\n3. Treatment \\> 6 h after symptom onset\n4. Allergy to statin medications or presence of severe adverse reactions such as abnormal liver function or rhabdomyolysis\n5. Evidence of irreversible brain damage or expected death within 7 days\n6. Known severe liver or kidney disease\n7. Non-compliance with follow-up\n8. Pregnant or breastfeeding\n9. History of severe cranial or psychiatric illness\n10. Concomitant serious systemic disease\n11. Patients with malignant tumors\n12. Currently participating in another clinical trial\n13. Considered unsuitable for the clinical trial by clinical physicians or researchers",{"count":562,"type":22},522,[564],"PHASE3","A researcher-initiated and conducted multicenter, randomized controlled trial aimed at evaluating the efficacy and safety of ultra-early statin therapy in the treatment of acute aneurysmal subarachnoid hemorrhage (aSAH).",[190,28,537,567],"Hemorrhage, Aneurysmal Subarachnoid",[31,569,570],"atorvastatin","Atorvastatin Calcium","2024-09-01",{"date":573,"type":40},"2024-09-05",{"date":571,"type":22},{"date":576,"type":22},"2026-09-01",{"name":578,"class":47},"The George Institute",{"id":580,"slug":581,"hasResults":11,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":72},"100446624","phase-4-the-anaesthetic-ketamine-as-treatment-for-patients-with-severe-acute-brain-injury-100446624","NCT05095857","The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury","S-ketamine for Cortical Spreading Depolarisation in Patients With Severe Acute Brain Injury","KETA-BID","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Admitted to the NICU with a diagnosis of traumatic brain injury (TBI), aneurysmal subarachnoid haemorrhage (aSAH) or spontaneous intracerebral haemorrhage (ICH).\n* Planned for surgery with a supratentorial craniotomy or craniectomy.\n* Expected to continue sedation and mechanical ventilation after surgery.\n\nExclusion Criteria:\n\n* Neither patient or next of kin understand Danish or English.\n* Known allergy to S-ketamine (the active pharmaceutical ingredient or the excipients).\n* Wake-up call to occur immediately after surgery.\n* Pregnancy (all female participants aged ≤ 50 years will have a urine or blood hCG taken to control for pregnancy).\n* Active anti-psychotic treatment before admission.\n* Current abuse of ketamine.\n* Decision to withdraw active treatment.\n* ICH secondary to a known brain tumour at the time of inclusion.\n\nSince this is an emergency trial informed consent will be obtained from a trial guardian before inclusion of the participant, and informed consent will be sought from next of kin as soon as possible.",{"count":588,"type":22},400,[304],"Cortical spreading depolarisations are pathological depolarisation waves that occur frequently after severe acute brain injury and has been associated with poor outcome. S-ketamine has been shown to inhibit cortical spreading depolarisations. The aim of the present study is to examine the efficacy and safety of using S-ketamine for treatment of patients with severe acute brain injury, as well as the feasibility of the trial design.",[28,219,592],"Traumatic Brain Injury",[594,595],"Cortical Spreading Depolarisation","Ketamine","2024-06-24",{"date":598,"type":40},"2024-06-26",{"date":600,"type":40},"2023-09-15",{"date":602,"type":22},"2028-09-15",{"name":604,"class":47},"Rigshospitalet, Denmark",{"id":606,"slug":607,"hasResults":11,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":481,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":612,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":614,"conditions":615,"keywords":618,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":72},"100551186","epidemiological-insights-into-the-formation-progression-and-rupture-of-intracranial-aneurysms-a-retrospective-multi-center-hospital-based-study-in-china-100551186","NCT06456814","Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China","Epidemiological Insights Into the Formation, Progression, and Rupture of Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China","Inclusion Criteria:\n\n1. IA diagnosis (ruptured or unruptured) or exclusion by digital subtractive angiography (DSA) or by cranial computed tomography angiography (CTA) \u002F magnetic resonance angiography (MRA);\n2. Aged ≥ 18 and ≤ 18 years old;\n3. With complete demographic data including age and sex;\n4. With medical record archiving officially.\n\nExclusion Criteria:\n\n1. Missing data of age, sex or hypertensive status;\n2. Age \\\u003C18 or \\>80 years;\n3. Pregnancy;\n4. With a history of intracranial arteriovenous malformation, Moyamoya, polycystic kidney disease, Ehlers-Danlos syndrome, Gronblad-Strandberg syndrome, or Marfan syndrome;\n5. Suspicion for dissecting or mycotic aneurysms or aneurysm-like lesions that were indistinguishable from the infundibulum, fenestration, dilation, or atherosclerotic remodeling on structural imaging scans.",{"count":613,"type":22},30000,"This is a retrospective, hospital-based and multi-center study aiming at investigating the potential exposures associated with the formation, progression, and rupture of intracranial aneurysms in Chinese population.",[92,28,616,617],"Cerebral Aneurysm","Brain Aneurysm",[619,620,621],"Intracranial aneurysm","Clinical epidemiology","Exposures","2024-06-07",{"date":624,"type":40},"2024-06-13",{"date":626,"type":40},"2010-01-01",{"date":628,"type":22},"2026-12-31",{"name":630,"class":47},"Zhujiang Hospital",{"id":632,"slug":633,"hasResults":11,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":72},"100532887","hemodynamic-instability-of-patient-with-spontaneous-subarachnoid-hemorrhage-100532887","NCT06218654","Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage","Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage and Systemic Response to Endogenous Stress. Urinary and Serum Factors and Clinical Developments. Pilot Study Toward the Predictivity of Clinical Failure and Variation on Outcome in the Neurosurgical Patient (HISAHES)","HISAHES","Inclusion Criteria:\n\n* Patients with spontaneous subarachnoid hemorrhage, including those with perimesencephalic subarachnoid hemorrhage and aneurysmal subarachnoid hemorrhage.\n* Adult patients.\n* Confirmed presence of spontaneous subarachnoid hemorrhage through neuroimaging.\n* Obtained informed consent for specific study biomarkers\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Post-traumatic subarachnoid hemorrhage.",{"count":640,"type":22},90,"The goal of this observational study is to learn about the role of biomarkers in spontaneous subarachnoid hemorrhage (sSAH) as predictors of severity of clinical outcome. The test of biomarkers is based on regular blood and urinary samples. Blood levels of highly specific cardiac troponin (cTNI), natriuretic peptides (NT-ProBNP), S100 beta protein, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase (UCH-L1), soluble Tumor Necrosis Factor Receptor-2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR), as well as urinary levels of epinephrine and norepinephrine are the biomarkers explored. All adult participants with spontaneous subarachnoid hemorrhage are involved in the study.\n\nThe main questions aim to answer are:\n\n* which of these molecules can be prognostic for patients' outcome\n* which are the prognostic levels of these biomarkers to predict patients' outcome.\n\nParticipants will undergo blood and urinary samples during hospitalization at 24 hours, 72 hours and after 7 days.",[643,28],"Subarachnoid Hemorrhage, Spontaneous","2024-04-10",{"date":646,"type":40},"2024-04-11",{"date":648,"type":40},"2024-01-15",{"date":650,"type":22},"2026-07-31",{"name":652,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":654,"slug":655,"hasResults":11,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":661,"targetDuration":663,"studyType":59,"phases":4,"briefSummary":664,"conditions":665,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":676},"100435084","poor-grade-aneurysmal-subarachnoid-hemorrhage-study-group-100435084","NCT04945603","Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group","Poor Grade Aneurysmal Subarachnoid Hemorrhage Multicentric Study Group","POGASH","Inclusion Criteria:\n\n* Patients admitted to the emergency department because of aneurysmal subarachnoid hemorrhage of poor grade (IV-V) according to the WFNS classification.\n\nExclusion Criteria:\n\n* Patients younger than 18 years old.\n* Pregnant or breast-feeding patients.\n* Aneurysmal subarachnoid hemorrhage due to trauma or vascular malformations other than cerebral aneurysms.",{"count":662,"type":22},800,"3 Years","Multicentric registry study in order to define outcome, predictors, treatment effects and their modifiers in poor grade aneurysmal subarachnoid haemorrhage patients.\n\nThe search for outcome predictors is going to be subdivided into three main research areas:\n\n1. outcome predictors in the emergency department (so called \"early brain injury phase\").\n2. outcome predictors in the neurocritical care unit (so called \"delayed brain injury phase\").\n3. Treatment strategies. Two other areas of research are identified: delayed cerebral ischemia (incidence, treatment, predictors, impact on outcome) and long term follow-up (recent evidences suggest that there may be a non-negligible proportion of poor grade subarachnoid hemorrhage patients who may benefit from substantial improvement at long-term (after 6-12 months of follow-up).",[28,666],"Poor Grade Subarachnoid Hemorrhage","2023-11-24",{"date":669,"type":40},"2023-11-29",{"date":671,"type":40},"2021-05-25",{"date":673,"type":22},"2028-12-31",{"name":675,"class":47},"IRCCS San Raffaele",10]